Fund I Investment Thesis: Vertical AI in Regulated Markets

Northbarn Capital closed its first fund in March 2019. We raised $60 million from a concentrated set of institutional limited partners — family offices, a university endowment, and two healthcare system strategic LPs — who share our conviction that regulated industries are not a difficult domain for AI companies to enter, but rather the most durable one.

We write this piece for three audiences: founders who are evaluating whether Northbarn is the right investor for their company, LPs who want a clear statement of what we are investing in, and our future selves — so that we can return to this document in five years and assess how well we understood the opportunity we are trying to capture.

The Core Thesis

The AI investment thesis that dominated 2017 and 2018 was largely horizontal: foundation models, infrastructure, and platforms that could serve any industry. We have a different view. The most defensible AI companies over the next decade will not be horizontal ones. They will be companies that have gone deep into a single regulated domain and encoded that domain's complexity — its workflows, its compliance requirements, its institutional buyer expectations — into their core product.

Healthcare, legal, and financial services represent roughly 40% of US GDP and are structurally underserved by technology precisely because the compliance and institutional constraints that protect their customers from harm also create friction for software adoption. We believe AI changes this equation: for the first time, the cost of encoding domain expertise into software is declining rapidly enough that vertical-first AI companies can achieve the depth previously only available to incumbent enterprise platforms built over decades.

What We Are Looking For

We concentrate at Series A. Not because we believe early is wrong — it is often right — but because we believe the highest-signal investment moment in a regulated-industry AI company is when it has demonstrated that it can navigate institutional procurement, execute on a business associate agreement or equivalent compliance review, and deliver measurable outcomes in a real clinical, legal, or financial workflow. At that moment, the question shifts from "can they build it?" to "can they scale it?" — and that is a question we think we are well-positioned to help answer.

We look for founding teams with at least one operator who has worked inside the domain they are building for. Not because domain expertise is sufficient — it is not — but because the procurement and integration conversations that regulated enterprises require are almost impossible to navigate without it. A team that has seen a vendor onboarding process from the inside will design their product differently than one that has not.